Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same

Abstract

An anti-aggregation agent of the present invention contains, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof. According to the present invention, in a container whose inner wall is treated with silicone oil, aggregation of a poorly water-soluble drug caused by the silicone oil can be prevented.

Claims

1. An anti-aggregation agent for preventing aggregation of a poorly water-soluble drug caused by silicone oil, comprising, as an anti-aggregation ingredient, at least one selected from the group consisting of polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 and combinations thereof.

2. A pharmaceutical composition comprising a poorly water-soluble drug and the anti-aggregation agent according to claim 1 in the presence of silicone oil.

3. The pharmaceutical composition according to claim 2, wherein the anti-aggregation agent contains the anti-aggregation ingredient in an amount of 2 to 40 parts by mass with respect to 100 parts by mass of the drug.

4. The pharmaceutical composition according to claim 2, wherein the silicone oil is derived from an inner wall of a container, and the inner wall being treated with silicone oil.

5. The pharmaceutical composition according to claim 2, which is obtained through lyophilization.

6. A medical device comprising a container whose inner wall is treated with silicone oil, wherein a poorly water-soluble drug and the anti-aggregation agent according to claim 1 are accommodated in the container.

7. The medical device according to claim 6, which has a form of a prefilled syringe.

8. The medical device according to claim 6, wherein the anti-aggregation agent contains the anti-aggregation ingredient in an amount of 2 to 40 parts by mass with respect to 100 parts by mass of the drug.

Description

DESCRIPTION OF THE INVENTION

[0021] Hereinafter, the present invention will be described in detail.

[0022] (1) Anti-Aggregation Agent

[0023] An anti-aggregation agent of the present invention is a composition used to prevent aggregation of a poorly water-soluble drug caused by silicone oil.

[0024] (Silicone Oil)

[0025] The term “silicone oil” as used herein encompasses silicone oils and silicone oil derivatives that can be used in pharmaceutical applications, as well as combinations thereof. A more specific example of the silicone oils is dimethylpolysiloxane. More specific examples of the silicone oil derivatives include those in which a portion of a side chain and/or an end of silicone is substituted with a polyoxyalkylene group or a vinyl group, for example.

[0026] The average molecular weight of silicone constituting silicone oil is, without limitation, preferably 10 to 100,000,000, more preferably 100 to 10,000,000, and even more preferably 200 to 10,000.

[0027] (Poorly Water-Soluble Drug)

[0028] The term “poorly water-soluble drug” as used herein encompasses drugs that are classified as “sparingly soluble”, “slightly soluble”, “very slightly soluble”, or “practically insoluble” as defined in the Japanese Pharmacopoeia. More specifically, the term “poorly water-soluble drug” encompasses drugs with respect to which, for example, when 1 g or 1 mL of a solute (drug) is added to a solvent (water) and the mixture at 20±5° C. is shaken vigorously for 30 seconds every 5 minutes, the amount of solvent (water) required for dissolving the solute within 30 minutes is from 30 mL to less than 100 mL, from 100 mL to less than 1000 mL, from 1000 mL to less than 10000 mL, and 10000 mL or more.

[0029] Examples of the poorly water-soluble drug include, but are not limited to, aripiprazole, candesartan, ezetimibe, atorvastatin, tolvaptan, sorafenib, paclitaxel, adriamycin, camptothecin, cipslatin, daunomycin, Pinorubin, methotrexate, mitomycin C, etoposide, gefitinib, irinotecan hydrochloride, topotecan hydrochloride, docetaxol, vinblastine sulfate, vincristine sulfate, vindesine sulfate, teniposide, vinorelbine tartrate, busulfan, carboquone, thiotepa, cyclophosphamide, melphalan, estramustine phosphate sodium, mechlorethamine oxide hydrochloride, ifosfamide, ranimustine, nimustine hydrochloride, bleomycin hydrochloride, peplomycin sulfate, zinostatin stimulate, actinomycin D, aclarubicin hydrochloride, doxorubicin hydrochloride, idarubicin hydrochloride, amrubicin hydrochloride, daunorubicin hydrochloride, pirarubicin, epirubicin hydrochloride, valrubicin, mercaptopurine, fludarabine phosphate, cladribine, fluorouracil, tegafur, cytarabine, gemcitabine hydrochloride, cytarabine ocfosphate, capecitabine, lentinan, oxaliplatin, doxifluridine, carmofur, enocitabine, nedaplatin, carboplatin, fadrozole hydrochloride, anastrozole, exemestane, bicalutamide, flutamide, tamoxifen citrate, toremiphene citrate, tretinoin, pentostatin, L-asparaginase, dacarbazine, procarbazine hydrochloride, mitoxantrone hydrochloride, sobuzoxane, trastuzumab, rituximab, imatinib mesylate, 5-fluoro-2′-deoxyuridine, Ascre, Carbocrin, Kinolespan, Krestin, Picibanil, hydrocortisone, hydrocortisone acetate, prednisolone, methylprednisolone, prednisolone acetate, hydrocortisone acetate propionate, prednisolone valerate, dexamethasone, betamethasone, triamcinolone, clobetasone acetate, clobetasol propionate, fluocinonide, dexamethasone acetate, betamethasone valerate, triamcinolone acetonide, aspirin, salicylic acid, acetaminophen, methyl salicylate, glycol salicylate, mefenamic acid, flufenamic acid, indomethacin, diclofenac, ketoprofen, ibuprofen, flurbiprofen, fenoprofen, bufexamac, piroxicam, oxyphenbutazone, mepirizole, ibuprofen piconol, clidanac, phenylbutazone, naproxen, glycyrrhizin, glycyrrhetinic acid, azulene, camphor, thymol, 1-menthol, tolfenamic acid, sasapyrine, alclofenac, diclofenac, suprofen, loxoprofen, acemetacin, metiazinic acid, protizinic acid, sulindac, pranoprofen, fentiazac, diflunisal, tiaprofenic acid, oxaprozin, felbinac, bufexamac, dibucaine hydrochloride, ethyl aminobenzoate, procaine hydrochloride, lidocaine, tetracaine hydrochloride, lidocaine hydrochloride, telecine, benzyl alcohol, pramoxine hydrochloride, quatacaine hydrochloride, butanicaine hydrochloride, piperocaine hydrochloride, chlorobutanol, barbital, amobarbital, amobarbital sodium, phenobarbital, phenobarbital sodium, secobarbital sodium, pentobarbital calcium, hexobarbital, triclofos, bromovalerylurea, glutethimide, methaqualone, perlapine, nitrazepam, estazolam, flurazepam hydrochloride, flunitrazepam, estazolam, chloramphenicol, cefmetazole, bacitracin, penicillin, cephalexin, tetracycline, streptomycin, nystatin, erythromycin, fradiomycin sulfate, tolnaftate, tocopherol acetate, benzyl nicotinate, tolazoline, verapamil, caffeine, cyclandelate, acetylcholine, tocopherol nicotinate, nifedipine, dipyridamole, prenylamine lactate, efloxate, phenytoin, phenacemide, ethylphenacemide, ethotoin, primidone, phensuximide, nitrazepam, chronazepam, carbamazepine, clozobazone, phenopropamate, diphenhydramine, mequitazine, digoxin, digitoxin, ubidecarenone, phenytoin, diisopyramide, polythiazide, spironolactone, chlorthalidone, deserpidine, meptame, reserbine, mebutamate, prostaglandin F2a danazol, mepitiostane, and pharmaceutically acceptable salts, hydrates, and derivatives thereof.

[0030] (Anti-Aggregation Ingredient)

[0031] The anti-aggregation agent of the present invention contains an anti-aggregation ingredient. Examples of the anti-aggregation ingredient include polyoxyethylene cetyl ether, polyoxyethylene sorbitan fatty acid esters, and polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000, as well as combinations thereof.

[0032] Polyoxyethylene sorbitan fatty acid esters are obtained by the ester reaction of polyoxyethylene sorbitan with long-chain fatty acids (e.g., lauric acid, stearic acid, palmitic acid, oleic acid, and the like), and are also called polysorbates. Specific examples of the polyoxyethylene sorbitan fatty acid esters include polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), polysorbate 80 (Tween 80), polysorbate 85 (Tween 85), and polysorbate 120, as well as combinations thereof.

[0033] The polyoxyethylene polyoxypropylene glycols having an average molecular weight of 3000 to 13000 are Pluronic (registered trademark) type polyoxyethylene polyoxypropylene glycols, and preferably polyoxyethylene polyoxypropylene glycols having an average molecular weight of 5500 to 12500. Specific examples of such polyoxyethylene polyoxypropylene glycols include polyoxyethylene (160) polyoxypropylene (30) glycol and the like.

[0034] Note that, as used herein, the “average molecular weight” of polyoxyethylene polyoxypropylene glycols means the weight average molecular weight, and is measured by GPC (gel permeation chromatography), for example.

[0035] (Other Ingredients)

[0036] The anti-aggregation agent of the present invention is preferably composed only of the above-described anti-aggregation ingredient, but may also contain other ingredients, in addition to the anti-aggregation ingredient, as long as the effects of the present invention are not impaired. There is no particular limitation on the other ingredients, and known additives can be used. When the anti-aggregation agent contains any other ingredient, the content of the anti-aggregation ingredient in the anti-aggregation agent of the present invention is preferably 50% by mass or greater, more preferably 80% by mass or greater, and even more preferably 90% by mass or greater.

[0037] The anti-aggregation agent of the present invention is prepared, for example, in the form of a pharmaceutical composition in which it is mixed with a poorly water-soluble drug, then is accommodated in a container whose inner wall is treated with silicone oil, and prevents the drug from aggregating in the presence of silicone oil.

[0038] (2) Pharmaceutical Composition

[0039] The pharmaceutical composition of the present invention contains the poorly water-soluble drug and the anti-aggregation agent described above in the presence of silicone oil. The phrase “in the presence of silicone oil” as used herein includes both a state in which the silicone oil is completely or partially mixed with the poorly water-soluble drug and the anti-aggregation agent and a state in which the silicone oil is not mixed with the poorly water-soluble drug and the anti-aggregation agent but are at least in contact with the poorly water-soluble drug and the anti-aggregation agent.

[0040] The silicone oil in the pharmaceutical composition of the present invention is preferably derived from the inner wall of the container, the inner wall being treated with silicone oil. The phrase “inner wall being treated with silicone oil” as used herein refers to a state in which the silicone oil is applied to the inner wall (inner surface) of the container. For example, in the case where the container is a syringe, a predetermined amount of silicone oil is applied to the inner wall of the syringe (a syringe barrel and a pusher), and the silicone oil can function as a lubricant for the pusher sliding inside the syringe barrel and a stopper (sealing plug) provided at an end portion thereof. In the case where the container is a vial, the silicone oil applied to the inner wall can reduce the likelihood that part of the content (e.g., a drug solution) filled in the vial will remain in the vial after the content is discharged to the outside. That is to say, the necessity of preliminarily setting the amount of pharmaceutical composition to be filled in the vial with consideration given to such residual content can be eliminated.

[0041] The amount of silicone oil applied to the inner wall of the container is not necessarily limited. For example, in the case where the container is a syringe, an amount of silicone oil that is sufficient to maintain the slidability of the syringe is applied to the inner wall thereof. Alternatively, for example, in the case where the container is a vial, an amount of silicone oil that enables efficient discharge of the content in the vial is applied to the inner wall thereof.

[0042] Since the pharmaceutical composition of the present invention contains the poorly water-soluble drug and the anti-aggregation agent together, even if silicone oil is applied to an inner wall of a container accommodating these ingredients and is mixed or in contact with these ingredients, aggregation of the poorly water-soluble drug when this pharmaceutical composition is suspended in an aqueous dispersion medium, which will be described later, can be prevented.

[0043] In the pharmaceutical composition of the present invention, preferably, the anti-aggregation agent is contained such that the content of the anti-aggregation ingredient is 2 to 40 parts by mass with respect to 100 parts by mass of the poorly water-soluble drug. More preferably, the anti-aggregation agent is contained such that the content of the anti-aggregation ingredient is 3 to 30 parts by mass with respect to 100 parts by mass of the poorly water-soluble drug. When the content of the anti-aggregation ingredient is 2 parts by mass or more with respect to 100 parts by mass of the poorly water-soluble drug, aggregation of the poorly water-soluble drug in an aqueous dispersion medium can be efficiently suppressed even in the presence of silicone oil. When the content of the anti-aggregation ingredient is 40 parts by mass or less with respect to 100 parts by mass of the poorly water-soluble drug, the risk that part of the poorly water-soluble drug will be dissolved due to the effect of an excessively large amount of anti-aggregation ingredient, resulting in a change in the elution property of the drug can be avoided.

[0044] Alternatively, the content of the anti-aggregation ingredient may be set based on the amount of silicone oil present in the pharmaceutical composition. In one embodiment, the content of the anti-aggregation ingredient is preferably 0.4 to 500 parts by mass, and more preferably 1.0 to 50 parts by mass, with respect to 1 part by mass of the silicone oil. When the content of the anti-aggregation ingredient is 0.4 parts by mass or more with respect to 1 part by mass of the silicone oil, aggregation of the poorly water-soluble drug in an aqueous dispersion medium can be efficiently suppressed even in the presence of the silicone oil. When the content of the anti-aggregation ingredient is 500 parts by mass or less with respect to 1 part by mass of the poorly water-soluble drug, the risk that part of the poorly water-soluble drug will be dissolved due to the effect of an excessively large amount of anti-aggregation ingredient, resulting in a change in the elution property of the drug can be avoided.

[0045] In the case where silicone oil present in the pharmaceutical composition is derived from the silicone oil applied to the inner wall of the container accommodating the pharmaceutical composition, the content of the anti-aggregation ingredient can be set by estimating the amount of silicone oil present in the pharmaceutical composition assuming that the entire amount of the silicone oil applied to the inner wall of the container is mixed into and present in the pharmaceutical composition, although, in reality, not the entire amount of the silicone oil applied to the inner wall of the container becomes mixed into the pharmaceutical composition.

[0046] Note that the amount of silicone oil present in the pharmaceutical composition can be determined by extracting the silicone oil using an appropriate solvent (e.g., methyl isobutyl ketone) and performing quantitative analysis using, for example, inductively coupled plasma (ICP) optical emission spectroscopy or atomic absorption spectrometry.

[0047] (Other Additives)

[0048] The pharmaceutical composition of the present invention may also contain other additives, in addition to the poorly water-soluble drug and the anti-aggregation agent described above.

[0049] Examples of the other additives include, but are not necessarily limited to, other suspending agents, excipients, buffers, pH regulators, and lubricants, as well as combinations thereof.

[0050] Examples of the other suspending agents include cetylpyridinium chloride, gelatin, casein, lecithin, dextran, glycerol, acacia gum, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene castor oil derivatives, polyethylene glycols, dodecyltrimethylammonium bromide, polyoxyethylene stearate, colloidal silicon dioxide, phosphate, sodium dodecyl sulfate, carboxymethylcellulose calcium, hydroxypropyl cellulose, methylcellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose phthalate, non-crystalline cellulose, aluminum magnesium silicate, triethanolamine, polyvinyl alcohol, poloxamer, poloxamine, and charged phospholipids, as well as combinations thereof.

[0051] Examples of the excipients include mannitol, sucrose, maltose, xylitol, glucose, starch, and sorbitol, as well as combinations thereof.

[0052] Examples of the buffers include sodium phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, potassium phosphate, and tris(hydroxymethyl)aminomethane (Tris), as well as combinations thereof.

[0053] As examples of the pH regulators, basic pH regulators can be used. For example, acidic pH regulators such as hydrochloric acid and acetic acid can be used as acidic pH regulators, and basic pH regulators such as sodium hydroxide, potassium hydroxide, calcium carbonate, magnesium oxide, and magnesium hydroxide can be used.

[0054] Examples of the lubricants include stearic acid, stearyl sodium fumarate, magnesium stearate, calcium stearate, sucrose fatty acid esters, polyethylene glycol, light anhydrous silicic acid, hydrogenated oil, glycerin fatty acid esters, and talc, as well as combinations thereof.

[0055] As for the above-listed and other additives, an appropriate amount to be added can be chosen by a person skilled in the art, as long as the effects of the present invention provided by the above-described poorly water-soluble drug and the above-described anti-aggregation agent are not impaired.

[0056] (Shape and State)

[0057] The pharmaceutical composition of the present invention may be in any shape and any state, as long as it contains the above-described ingredients. For example, the pharmaceutical composition may be a lyophilized product in a solid state obtained by lyophilizing a suspension of the above-described ingredients dissolved or dispersed in an aqueous dispersion medium, or may be a suspension in a liquid state obtained by suspending the above-described ingredients in an aqueous dispersion medium. Preferably, the pharmaceutical composition of the present invention is obtained through lyophilization.

[0058] (3) Medical Device

[0059] The medical device of the present invention includes a container whose inner wall is treated with silicone oil.

[0060] The container constituting the medical device of the present invention can be sealed from the outside, for example. Examples of the container include prefilled syringes and vials, preferably prefilled syringes. Specific examples of the prefilled syringes include single-chamber syringes consisting of one syringe barrel and one pusher, as well as syringes that accommodate the contents separated into a plurality of compartments (chambers) (an example of such syringes is a double-chamber syringe with two compartments).

[0061] In the case where the medical device of the present invention includes a prefilled syringe as the container, it is preferable that the prefilled syringe has the form of a double-chamber syringe that accommodates a solid containing at least a poorly water-soluble drug in one compartment and accommodates an aqueous dispersion medium in the other compartment. In this case, the above-described anti-aggregation agent, and the above-described other additives contained in the pharmaceutical composition if necessary, may be contained in the solid or in the aqueous dispersion medium.

[0062] With a medical device that has the form of a double-chamber syringe as described above, the stability of the poorly water-soluble drug can be maintained because the drug is stored as a solid until use, and great convenience can be provided when suspending the solid by adding the aqueous dispersion medium to the solid at the time of use because the aqueous dispersion medium is accommodated in the device beforehand. Furthermore, with this configuration, the coexistence of the poorly water-soluble drug and the anti-aggregation agent is kept when suspending the solid, and therefore, even when silicone oil that is applied to the inner wall of the syringe in order to increase the slidability is mixed into (present in) the suspension, the poorly water-soluble drug can be prevented from aggregating in the suspension. Thus, the dissolution profile of the poorly water-soluble drug used itself is prevented from significantly deviating from the dissolution profile of the drug before coming into contact with the silicone oil, and substantially the same sustained-release properties and efficacy can be obtained. In addition, there is thus no concern about problems such as the clogging in the device and the physical irritation to the injection site of the patient due to the increased particle size.

[0063] There is no particular limitation on the material of the container constituting the medical device of the present invention, and examples include glass, thermoplastic resins such as olefin resins (polyethylene, polypropylene, etc.) and cyclo olefin polymer (COP), and the like.

[0064] The aqueous dispersion medium is water or a mixed medium of water and ethanol. Typically, water (water for injection) is used as the aqueous dispersion medium. Note that, as described above, the aqueous dispersion medium can contain the anti-aggregation agent and the other additives (among others, other suspending agents and/or pH regulators).

EXAMPLES

[0065] Hereinafter, the present invention will be described in greater detail using examples. However, the present invention is not limited to the examples below.

[0066] In all of the examples and comparative examples below, test suspensions were produced using a procedure that will be described below, and the volume average particle size of particles contained in the obtained suspensions was measured. In this regard, the following remarks are added in advance.

[0067] This procedure appears to be different from that which is assumed to be performed when using the medical device of the present invention and in which the poorly water-soluble drug and the anti-aggregation agent are accommodated in the container to which silicone oil is applied, and are then suspended in the aqueous dispersion medium. However, the two procedures are the same in that a poorly water-soluble drug is suspended in an aqueous dispersion medium in the presence of silicone oil. Therefore, the procedure below can be regarded as being equal to that of an example or a corresponding comparative example when a poorly water-soluble drug is suspended as assumed for the medical device of the present invention.

[0068] The volume average particle size of particles contained in the test suspensions obtained in the examples, comparative examples, and reference examples was measured in the following manner. That is, after a test suspension obtained was allowed to stand at room temperature for 5 minutes, the particle size (volume average particle size) of particles contained in this test suspension (a) was measured using a laser diffraction/scattering particle size distribution measurement apparatus (manufactured by HORIBA, Ltd. (LA-950)) (using a circulating cell and water as a measurement medium) (the results of this measurement will be referred to as “before ultrasonic treatment (a)”). Next, this test suspension (a) was ultrasonically treated for 1 minute using an ultrasonic generator attached to the particle size distribution measurement apparatus, and then, the particle size of particles contained in the resulting test suspension (b) after the ultrasonic treatment was measured in the same manner (the results of this measurement will be referred to as “after ultrasonic treatment (b)”).

Example 1: Test Suspensions Containing Aripiprazole

Example 1-1-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0069] An aripiprazole suspension was prepared by adding aripiprazole hydrate as a poorly water-soluble drug, carboxymethylcellulose sodium, mannitol, and sodium dihydrogen phosphate monohydrate to purified water to the following concentrations. [0070] Aripiprazole hydrate: 30% by mass (as anhydride) [0071] Carboxymethylcellulose sodium: about 1.248% by mass [0072] Mannitol: about 6.24% by mass [0073] Sodium dihydrogen phosphate monohydrate: about 0.111% by mass

[0074] To 1 g of the aripiprazole suspension was added polyoxyethylene cetyl ether as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension, followed by stirring. To this suspension was added a 1% silicone oil emulsion (Dow Corning (registered trademark) 365, 35% Dimethicone NF Elusion manufactured by DuPont; hereinafter simply referred to as “1% silicone oil emulsion”) such that the amount of silicone oil contained in the resulting suspension was 0.05 parts by mass with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, a test suspension (E1-1-1) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 1 shows the results.

Examples 1-1-2 to 1-1-7: Production and Evaluation of Test Suspensions Using Polyoxyethylene Cetyl Ether

[0075] To the test suspension (E1-1-1) (before ultrasonic treatment) obtained in Example 1-1-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 1 with respect to 100 parts by mass of aripiprazole, to thereby prepare test suspensions (E1-1-2) to (E1-1-7), and thus, the test suspensions (E1-1-2) to (E1-1-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 1 shows the results.

Reference Example 1-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0076] A test suspension (R1-1) was prepared in the same manner as in Example 1-1-1, except that the 1% silicone oil emulsion was not added, and thus, the test suspension (R1-1) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 1 shows the results.

TABLE-US-00001 TABLE 1 Reference Example Eample Example Example Example Example Example Example 1-1 1-1-1 1-1-2 1-1-3 1-1-4 1-1-5 1-1-6 1-1-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 4 4 4 4 4 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 80 40 20 8 4 1.6 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Particle Before Ultrasonic 4.21 4.47 4.37 4.51 4.49 3.59 4.18 4.39 Size (μm) Treatment (a) After Ultrasonic 3.38 3.56 4.18 3.74 3.59 3.46 3.55 3.93 Treatment (b) Difference 0.84 0.90 0.19 0.77 0.90 0.13 0.64 0.46 ((a) − (b)) .sup.1)Polyoxyethylene Cetyl Ether

Example 1-2-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0077] A test suspension (E1-2-1) was prepared in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polyoxyethylene cetyl ether was added as an anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension, and thus, the test suspension (E1-2-1) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 2 shows the results.

Examples 1-2-2 to 1-2-7: Production and Evaluation of Test Suspensions Using Polyoxyethylene Cetyl Ether

[0078] To the test suspension (E1-2-1) (before ultrasonic treatment) obtained in Example 1-2-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 2 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-2-2) to (E1-2-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 2 shows the results.

Reference Example 1-2: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0079] A test suspension (R1-2) was obtained in the same manner as in Example 1-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 2 shows the results.

TABLE-US-00002 TABLE 2 Reference Example Example Example Example Example Example Example Example 1-2 1-2-1 1-2-2 1-2-3 1-2-4 1-2-5 1-2-6 1-2-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 20 20 20 20 20 20 20 20 Agent.sup.1) Amount of Anti-Aggregation — 400 200 100 40 20 8 4 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before Ultrasonic 3.54 3.99 3.47 3.26 3.31 3.94 3.97 3.35 Size (μm) Treatment (a) After Ultrasonic 3.35 3.62 3.56 3.14 3.58 3.12 3.21 3.04 Treatment (b) Difference 0.19 0.38 −0.09 0.12 −0.27 0.81 0.76 0.3 ((a) − (b)) .sup.1)Polyoxyethylene Cetyl Ether

Example 1-3-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0080] A test suspension (E1-3-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polyoxyethylene (160) polyoxypropylene (30) glycol (having an average molecular weight of 8905) was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 3 shows the results.

Examples 1-3-2 to 1-3-7: Production and Evaluation of Test Suspensions Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0081] To the test suspension (E1-3-1) (before ultrasonic treatment) obtained in Example 1-3-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 3 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-3-2) to (E1-3-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 3 shows the results.

Reference Example 1-3: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0082] A test suspension (R1-3) was obtained in the same manner as in Example 1-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 3 shows the results.

TABLE-US-00003 TABLE 3 Reference Example Example Example Example Example Example Example Example 1-3 1-3-1 1-3-2 1-3-3 1-3-4 1-3-5 1-3-6 1-3-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 4 4 4 4 4 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 80 40 20 8 4 1.6 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before Ultrasonic 4.62 4.53 4.22 4.45 4.10 5.23 5.74 5.00 Size (μm) Treatment (a) After Ultrasonic 3.25 3.24 3.16 3.16 2.78 3.38 3.23 3.13 Treatment (b) Difference 1.37 1.29 1.07 1.29 1.32 1.85 2.51 1.87 ((a) − (b)) .sup.1)Polyoxyethylene (160) Polyoxypropylene (30) Glycol

Example 1-4-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0083] A test suspension (E1-4-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polyoxyethylene (160) polyoxypropylene (30) glycol (having an average molecular weight of 8905) was added as an anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 4 shows the results.

Examples 1-4-2 to 1-4-7: Production and Evaluation of Test Suspensions Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0084] To the test suspension (E1-4-1) (before ultrasonic treatment) obtained in Example 1-4-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 4 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-4-2) to (E1-4-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 4 shows the results.

Reference Example 1-4: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0085] A test suspension (R1-4) was obtained in the same manner as in Example 1-4-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 4 shows the results.

TABLE-US-00004 TABLE 4 Reference Example Example Example Example Example Example Example Example 1-4 1-4-1 1-4-2 1-4-3 1-4-4 1-4-5 1-4-6 1-4-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 20 20 20 20 20 20 20 20 Agent.sup.1) Amount of Anti-Aggregation — 400 200 100 40 20 8 4 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before Ultrasonic 3.89 3.46 3.39 3.44 3.65 3.26 3.13 3.18 size (μm) Treatment (a) After Ultrasonic 3.26 2.85 2.88 2.94 3.05 2.80 2.74 2.61 Treatment (b) Difference 0.63 0.61 0.51 0.50 0.61 0.46 0.39 0.57 ((a) − (b)) .sup.1)Polyoxyethylene (160) Polyoxypropylene (30) Glycol

Example 1-5-1: Production and Evaluation of Test Suspension Using Polysorbate 20

[0086] A test suspension (E1-5-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polysorbate 20 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 5 shows the results.

Examples 1-5-2 to 1-5-7: Production and Evaluation of Test Suspensions Using Polysorbate 20

[0087] To the test suspension (E1-5-1) (before ultrasonic treatment) obtained in Example 1-5-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 5 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-5-2) to (E1-5-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 5 shows the results.

Reference Example 1-5: Production and Evaluation of Test Suspension Using Polysorbate 20

[0088] A test suspension (R1-5) was obtained in the same manner as in Example 1-5-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 5 shows the results.

TABLE-US-00005 TABLE 5 Reference Example Example Example Example Example Example Example Example 1-5 1-5-1 1-5-2 1-5-3 1-5-4 1-5-5 1-5-6 1-5-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 4 4 4 4 4 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 80 40 20 8 4 1.6 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before Ultrasonic 4.58 4.22 4.06 4.45 4.24 4.70 4.33 4.54 Size (μm) Treatment (a) After Ultrasonic 3.79 3.74 3.83 3.72 3.86 3.97 3.88 3.26 Treatment (b) Difference 0.80 0.48 0.24 0.73 0.38 0.73 0.44 1.28 ((a) − (b)) .sup.1)Polysorbate 20

Example 1-6-1: Production and Evaluation of Test Suspension Using Polysorbate 20

[0089] A test suspension (E1-6-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polysorbate 20 was added as an anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 6 shows the results.

Examples 1-6-2 to 1-6-7: Production and Evaluation of Test Suspensions Using Polysorbate 20

[0090] To the test suspension (E1-6-1) (before ultrasonic treatment) obtained in Example 1-6-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 6 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-6-2) to (E1-6-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 6 shows the results.

Reference Example 1-6: Production and Evaluation of Test Suspension Using Polysorbate 20

[0091] A test suspension (R1-6) was obtained in the same manner as in Example 1-6-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 6 shows the results.

TABLE-US-00006 TABLE 6 Reference Example Example Example Example Example Example Example Example 1-6 1-6-1 1-6-2 1-6-3 1-6-4 1-6-5 1-6-6 1-6-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 20 20 20 20 20 20 20 20 Aent.sup.1) Amount of Anti-Aggregation — 400 200 100 40 20 8 4 Ingredient per 1 Part by Mass of Silicone oil (Parts by Mass) Average Particle Before Ultrasonic 3.55 3.99 3.88 3.97 4.20 3.99 4.04 3.85 Size (μm) Treatment (a) After Ultrasonic 3.41 3.60 3.66 3.87 3.61 3.57 3.68 3.53 Treatment (b) Difference 0.15 0.39 0.22 0.10 0.59 0.42 0.36 0.31 ((a) − (b)) .sup.1)Polysorbate 20

Example 1-7-1: Production and Evaluation of Test Suspension Using Polysorbate 80

[0092] A test suspension (E1-7-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polysorbate 80 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 7 shows the results.

Examples 1-7-2 to 1-7-7: Production and Evaluation of Test Suspensions Using Polysorbate 80

[0093] To the test suspension (E1-7-1) (before ultrasonic treatment) obtained in Example 1-7-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 7 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-7-2) to (E1-7-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 7 shows the results.

Reference Example 1-7: Production and Evaluation of Test Suspension Using Polysorbate 80

[0094] A test suspension (R1-7) was obtained in the same manner as in Example 1-7-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 7 shows the results.

TABLE-US-00007 TABLE 7 Reference Example Example Example Example Example Example Example Example 1-7 1-7-1 1-7-2 1-7-3 1-7-4 1-7-5 1-7-6 1-7-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 4 4 4 4 4 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 80 40 20 8 4 1.6 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before Ultrasonic 3.91 4.30 4.35 4.15 4.38 4.26 4.18 4.20 Size (μm) Treatment (a) After Ultrasonic 3.33 3.50 3.54 3.46 3.61 3.58 3.51 3.49 Treatment (b) Difference 0.59 0.80 0.80 0.69 0.77 0.68 0.66 0.71 ((a) − (b)) .sup.1)Polysorbate 80

Example 1-8-1: Production and Evaluation of Test Suspension Using Polysorbate 80

[0095] A test suspension (E1-8-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polysorbate 80 was added as an anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 8 shows the results.

Examples 1-8-2 to 1-8-7: Production and Evaluation of Test Suspensions Using Polysorbate 80

[0096] To the test suspension (E1-8-1) (before ultrasonic treatment) obtained in Example 1-8-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 8 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (E1-8-2) to (E1-8-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 8 shows the results.

Reference Example 1-8: Production and Evaluation of Test Suspension Using Polysorbate 80

[0097] A test suspension (R1-8) was obtained in the same manner as in Example 1-8-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 8 shows the results.

TABLE-US-00008 TABLE 8 Reference Example Example Example Example Example Example Example Example 1-8 1-8-1 1-8-2 1-8-3 1-8-4 1-8-5 1-8-6 1-8-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 20 20 20 20 20 20 20 20 Agent.sup.1) Amount of Anti-Aggregation — 400 200 100 40 20 8 4 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before Ultrasonic 3.67 3.90 3.87 3.85 3.79 4.00 3.97 3.60 Size (μm) Treatment (a) After Ultrasonic 3.25 3.95 3.75 3.74 3.81 3.96 3.79 3.38 Treatment (b) Difference 0.43 −0.05 0.11 0.11 −0.01 0.04 0.17 0.22 ((a) − (b)) .sup.1)Polysorbate 80

Comparative Example 1-1-1: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0098] A test suspension (C1-1-1) was obtained in the same manner as in Example 1-1-1, except that no anti-aggregation agent was added to 1 g of the aripiprazole suspension prepared in Example 1-1-1. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 9 shows the results.

Comparative Examples 1-1-2 to 1-1-7: Production and Evaluation of Test Suspensions (Blanks) Containing No Anti-Aggregation Agent

[0099] To the test suspension (C1-1-1) (before ultrasonic treatment) obtained in Comparative Example 1-1-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 9 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (C1-1-2) to (C1-1-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 9 shows the results.

Comparative Reference Example 1-1: Production and Evaluation of Test Suspension Containing No Anti-Aggregation Agent

[0100] A test suspension (CR1-1) was obtained in the same manner as in Comparative Example 1-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 9 shows the results.

TABLE-US-00009 TABLE 9 Comparative Comparative Compative Compative Compative Compative Compative Compative Reference Example Example Example Example Example Example Example Example1-1 1-1-1 1-1-2 1-1-3 1-1-4 1-1-5 1-1-6 1-1-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti-Aggregation 0 0 0 0 0 0 0 0 Agent Amount of Anti-Aggregation — 0 0 0 0 0 0 0 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Particle Before ultrasonic 3.57 3.52 3.94 5.44 8.53 8.10 13.20 14.49 Size (μm) treatment (a) After ultrasonic 3.67 3.44 3.56 3.57 4.57 6.00 7.72 9.80 treatment (b) Difference −0.09 0.07 0.38 1.87 3.96 2.11 5.48 4.68 ((a) − (b))

Reference Example 1-2-1: Production and Evaluation of Test Suspension Using Sodium Lauryl Sulfate

[0101] A test suspension (C1-2-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, sodium lauryl sulfate was added instead of the anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 10 shows the results.

Comparative Reference Example 1-2: Production and Evaluation of Test Suspension Using Sodium Lauryl Sulfate

[0102] A test suspension (CR1-2) was obtained in the same manner as in Comparative Example 1-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 10 shows the results.

TABLE-US-00010 TABLE 10 Comparative Comparative Reference Exmple Example 1-2 1-2-1 Ingredients Aripiprazole 100 100 (Parts by Silicone oil  0  0.05 mass) Anti-aggregation  0  0 agent Sodium lauryl  20  20 sulfate Amount of anti-aggregation — — ingredient per 1 part by mass of silicone oil (Parts by mass) Average Before ultrasonic  3.86  4.86 particle treatment (a) size After ultrasonic  3.77  5.82 (μm) treatment (b) Difference ((a)-(b))  0.10  −0.96

Comparative Example 1-3-1: Production and Evaluation of Test Suspension Using Sodium Lauroylsarcosinate

[0103] A test suspension (C1-3-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, sodium lauroylsarcosinate was added instead of the anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 11 shows the results.

Comparative Examples 1-3-2 to 1-3-7: Production and Evaluation of Test Suspensions Using Sodium Lauroylsarcosinate

[0104] To the test suspension (C1-3-1) (before ultrasonic treatment) obtained in Comparative Example 1-3-1 was added the 1% silicone oil emulsion such that the amounts of silicone oil contained in the resulting suspensions were as shown in Table 11 with respect to 100 parts by mass of aripiprazole, followed by stirring, and thus, test suspensions (C1-3-2) to (C1-3-7) were obtained. The particle size of particles contained in each test suspension before ultrasonic treatment (a) and the particle size of particles contained in each test suspension after ultrasonic treatment (b) were measured. Table 11 shows the results.

Comparative Reference Example 1-3: Production and Evaluation of Test Suspension Using Sodium Lauroylsarcosinate

[0105] A test suspension (CR1-3) was obtained in the same manner as in Comparative Example 1-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 11 shows the results.

TABLE-US-00011 TABLE 11 Comparative Comparative Comparative Comparative Comparative Comparative Comparative Comparative Reference Example Example Example Example Example Example Example Example 1-3 1-3-1 1-3-2 1-3-3 1-3-4 1-3-5 1-3-6 1-3-7 Ingredients Aripiprazole 100 100 100 100 100 100 100 100 (Parts by Mass) Silicone Oil 0 0.05 0.1 0.2 0.5 1 2.5 5 Anti- 0 0 0 0 0 0 0 0 Aggregation Agent Sodium 20 20 20 20 20 20 20 20 Lauroyl- sarcosinate Amount of Anti-Aggregation — — — — — — — — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 4.63 4.35 5.41 4.19 4.09 4.46 4.64 5.99 Particle Treatment (a) Size (μm) After Ultrasonic 4.08 3.82 4.68 5.31 4.00 5.87 6.63 9.32 Treatment (b) Difference 0.55 0.53 0.73 −1.12 0.09 −1.40 −1.99 −3.34 ((a) − (b))

Comparative Example 1-4-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0106] A test suspension (C1-4-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, polyoxyethylene (20) polyoxypropylene (20) glycol (having an average molecular weight of approximately 2000 (and less than 3000)) was added instead of the anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension, and the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 12 shows the results. Note that the test suspension (C1-4-1) lost its fluidity and ultimately solidified.

TABLE-US-00012 TABLE 12 Comparative Example 1-4-1 Ingredients Aripiprazole 100 (Parts by Silicone Oil 0 Mass) Anti-Aggregation Agent 0 Polyoxyethylene (20) 4 Polyoxypropylene (20) Glycol Amount of Anti-Aggregation Ingredient — per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 7.84 Particle Treatment (a) Size (μm) After Ultrasonic 3.17 Treatment (b) Difference ((a)-(b)) 4.67

Comparative Example 1-5-1: Production and Evaluation of Test Suspension Using Macrogol 400

[0107] A test suspension (C1-5-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, macrogol 400 was added instead of the anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension, and the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 13 shows the results. Note that the test suspension (C1-5-1) lost its fluidity and ultimately solidified.

TABLE-US-00013 TABLE 13 Comparative Example 1-5-1 Ingredients Aripiprazole 100 (Parts by Silicone Oil 0 Mass) Anti-Aggregation 0 Agent Macrogol 400 4 Amount of Anti-Aggregation — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 5.74 Particle Treatment (a) Size After Ultrasonic 5.51 (μm) Treatment (b) Difference ((a)-(b)) 0.23

Comparative Example 1-6-1: Production and Evaluation of Test Suspension Using Macrogol 400

[0108] A test suspension (C1-6-1) was obtained in the same manner as in Example 1-1-1, except that, to 1 g of the aripiprazole suspension prepared in Example 1-1-1, macrogol 400 was added instead of the anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of aripiprazole contained in the suspension, and the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 14 shows the results. Note that the test suspension (C1-6-1) lost its fluidity and ultimately solidified.

TABLE-US-00014 TABLE 14 Comparative Example 1-6-1 Ingredients Aripiprazole 100 (Parts by Silicone Oil 0 Mass) Anti-Aggregation 0 Agent Macrogol 400 20 Amount of Anti-Aggregation — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 5.22 Particle Treatment (a) Size After Ultrasonic 3.11 (μm) Treatment (b) Difference ((a)-(b)) 2.11

[0109] As is clear from Tables 1 to 14 above, it can be seen that even though the test suspensions produced in the examples above contained silicone oil, aggregation of aripiprazole was appropriately prevented by the anti-aggregation agents.

Example 2: Test Suspensions Containing Ezetimibe Example 2-1-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0110] An ezetimibe suspension was prepared by adding ezetimibe as a poorly water-soluble drug, carboxymethylcellulose sodium, mannitol, and sodium dihydrogen phosphate monohydrate to purified water to the following concentrations. [0111] Ezetimibe: 30% by mass [0112] Carboxymethylcellulose sodium: about 1.248% by mass [0113] Mannitol: about 6.24% by mass [0114] Sodium dihydrogen phosphate monohydrate: about 0.111% by mass

[0115] To 1 g of the ezetimibe suspension was added polyoxyethylene cetyl ether as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension, followed by stirring. To this suspension was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 0.5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-1-1) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 15 shows the results.

Example 2-1-2: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0116] To the test suspension (E2-1-1) (before ultrasonic treatment) obtained in Example 2-1-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-1-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 15 shows the results.

Reference Example 2-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0117] A test suspension (R2-1) was obtained in the same manner as in Example 2-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 15 shows the results.

TABLE-US-00015 TABLE 15 Reference Example Example Example 2-1 2-1-1 2-1-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 3.74 3.63 3.86 Particle Treatment (a) Size After Ultrasonic 2.54 2.32 2.70 (μm) Treatment (b) Difference ((a)-(b)) 1.20 1.31 1.16 .sup.1)Polyoxyethylene Cetyl Ether

Example 2-2-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0118] A test suspension (E2-2-1) was obtained in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, polyoxyethylene (160) polyoxypropylene (30) glycol (having an average molecular weight of 8905) was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 16 shows the results.

Example 2-2-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0119] To the test suspension (E2-2-1) (before ultrasonic treatment) obtained in Example 2-2-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-2-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 16 shows the results.

Reference Example 2-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0120] A test suspension (R2-2) was obtained in the same manner as in Example 2-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 16 shows the results.

TABLE-US-00016 TABLE 16 Reference Example Example Example 2-2 2-2-1 2-2-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 4.16 5.06 5.33 Particle Treatment (a) Size After Ultrasonic 2.61 2.62 2.97 (μm) Treatment (b) Difference ((a)-(b)) 1.55 2.44 2.36 .sup.1)Polyoxyethylene (160) Polyoxypropylene (30) Glycol

Example 2-3-1: Production and Evaluation of Test Suspension Using Polysorbate 20

[0121] A test suspension (E2-3-1) was obtained in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, polysorbate 20 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 17 shows the results.

T Example 2-3-2: Production and Evaluation of Test Suspension Using Polysorbate 20

[0122] the test suspension (E2-3-1) (before ultrasonic treatment) obtained in Example 2-3-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-3-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 17 shows the results.

Reference Example 2-3: Production and Evaluation of Test Suspension Using Polysorbate 20

[0123] A test suspension (R2-3) was obtained in the same manner as in Example 2-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 17 shows the results.

TABLE-US-00017 TABLE 17 Reference Example Example Example 2-3 2-3-1 2-3-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 5.26 6.96 10.15 Particle Treatment (a) Size After Ultrasonic 2.84 2.98 5.56 (μm) Treatment (b) Difference ((a)-(b)) 2.42 3.98 4.59 .sup.1)Polysorbate 20

Example 2-4-1: Production and Evaluation of Test Suspension Using Polysorbate 20

[0124] A test suspension (E2-4-1) was obtained in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, polysorbate 20 was added as an anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 18 shows the results.

Example 2-4-2: Production and Evaluation of Test Suspension Using Polysorbate 20

[0125] To the test suspension (E2-4-1) (before ultrasonic treatment) obtained in Example 2-4-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-4-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 18 shows the results.

Reference Example 2-4: Production and Evaluation of Test Suspension Using Polysorbate 20

[0126] A test suspension (R2-4) was obtained in the same manner as in Example 2-4-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 18 shows the results.

TABLE-US-00018 TABLE 18 Reference Example Example Example 2-4 2-4-1 2-4-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 20 20 20 Agent.sup.1) Amount of Anti-Aggregation — 40 4 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 3.55 5.93 6.96 Particle Treatment (a) Size After Ultrasonic 2.66 2.73 2.74 (μm) Treatment (b) Difference ((a)-(b)) 0.89 3.20 4.22 .sup.1)Polysorbate 20

Example 2-5-1: Production and Evaluation of Test Suspension Using Polysorbate 80

[0127] A test suspension (E2-5-1) was obtained in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, polysorbate 80 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 19 shows the results.

Example 2-5-2: Production and Evaluation of Test Suspension Using Polysorbate 80

[0128] To the test suspension (E2-5-1) (before ultrasonic treatment) obtained in Example 2-5-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-5-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 19 shows the results.

Reference Example 2-5: Production and Evaluation of Test Suspension Using Polysorbate 80

[0129] A test suspension (R2-5) was obtained in the same manner as in Example 2-5-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 19 shows the results.

TABLE-US-00019 TABLE 19 Reference Example Example Example 2-5 2-5-1 2-5-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil  0  0.5  5 Mass) Anti-Aggregation  4  4  4 Agent.sup.1) Amount of Anti-Aggregation —  8  0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic  3.65  4.16  5.32 Particle Size Treatment (a) (μm) After Ultrasonic  2.32  2.71  2.96 Treatment (b) Difference ((a)-(b))  1.33  1.45  2.36 .sup.1)Polysorbate 80

Example 2-6-1: Production and Evaluation of Test Suspension Using Polysorbate 80

[0130] A test suspension (E2-6-1) was obtained in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, polysorbate 80 was added as an anti-aggregation agent in an amount corresponding to 20 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 20 shows the results.

Example 2-6-2: Production and Evaluation of Test Suspension Using Polysorbate 80

[0131] To the test suspension (E2-6-1) (before ultrasonic treatment) obtained in Example 2-6-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (E2-6-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 20 shows the results.

Reference Example 2-6: Production and Evaluation of Test Suspension Using Polysorbate 80

[0132] A test suspension (R2-6) was obtained in the same manner as in Example 2-6-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 20 shows the results.

TABLE-US-00020 TABLE 20 Reference Example Example Example 2-6 2-6-1 2-6-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 20 20 20 Agent.sup.1) Amount of Anti-Aggregation — 40 4 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 3.63 3.63 4.18 Particle Treatment (a) Size After Ultrasonic 2.48 2.71 2.71 (μm) Treatment (b) Difference ((a)-(b)) 1.15 0.92 1.47 .sup.1)Polysorbate 80

Comparative Example 2-1-1: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0133] A test suspension (C2-1-1) was obtained in the same manner as in Example 2-1-1, except that no anti-aggregation agent was added to 1 g of the ezetimibe suspension prepared in Example 2-1-1. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 21 shows the results.

Comparative Example 2-1-2: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0134] To the test suspension (C2-1-1) (before ultrasonic treatment) obtained in Comparative Example 2-1-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (C2-1-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 21 shows the results.

Comparative Reference Example 2-1: Production and Evaluation of Test Suspension Containing No Anti-Aggregation Agent

[0135] A test suspension (CR2-1) was obtained in the same manner as in Comparative Example 2-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 21 shows the results.

TABLE-US-00021 TABLE 2 Com- Com- Com- parative parative parative Reference Example Example Example 2-1 2-1-1 2-1-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 0 0 0 Agent Amount of Anti-Aggregation — 0 0 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 5.04 6.42 17.07 Particle Treatment (a) Size After Ultrasonic 3.08 3.17 12.08 (μm) Treatment (b) Difference ((a) − (b)) 1.96 3.25 4.99

Comparative Example 2-2-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0136] A test suspension (C2-2-1) was prepared in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, polyoxyethylene (20) polyoxypropylene (20) glycol (having an average molecular weight of approximately 2000 (and less than 3000) was added instead of the anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension. However, measurement of the particle size of particles (before ultrasonic treatment (a) and after ultrasonic treatment (b)) was not performed (Table 22), because this test suspension (C2-2-1) had already lost its fluidity and solidified, and apparent aggregation was observed visually.

Comparative Example 2-2-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0137] To the test suspension (C2-2-1) (before ultrasonic treatment) obtained in Comparative Example 2-2-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (C2-2-2) was prepared. However, measurement of the particle size of particles (before ultrasonic treatment (a) and after ultrasonic treatment (b)) was not performed (Table 22), because this test suspension (C2-2-2) had already lost its fluidity and solidified, and apparent aggregation was observed visually.

Comparative Reference Example 2-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0138] A test suspension (CR2-2) was obtained in the same manner as in Comparative Example 2-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 22 shows the results. Note that the test suspension (CR2-2) lost its fluidity and was partially solidified.

TABLE-US-00022 TABLE 22 Com- Com- Com- parative parative parative Reference Example Example Example 2-2 2-2-1 2-2-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 0 0 0 Agent Polyoxyethylene (20) 4 4 4 Polyoxypropylene (20) Glycol Amount of Anti-Aggregation — — — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 10.26 the fluidity was lost Particle Treatment (a) Size After Ultrasonic 3.26 not to measured (μm) Treatment (b) Difference ((a) − (b)) 7.00

Comparative Example 2-3-1: Production and Evaluation of Test Suspension Using Macrogol 400

[0139] A test suspension (C2-3-1) was prepared in the same manner as in Example 2-1-1, except that, to 1 g of the ezetimibe suspension prepared in Example 2-1-1, macrogol 400 was added instead of the anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of ezetimibe contained in the suspension, and the 1% silicone oil emulsion was not added. However, measurement of the particle size of particles (before ultrasonic treatment (a) and after ultrasonic treatment (b)) was not performed (Table 23), because this test suspension (C2-3-1) had already lost its fluidity and solidified, and apparent aggregation was observed visually.

Comparative Example 2-3-2: Production and Evaluation of Test Suspension Using Macrogol 400

[0140] To the test suspension (C2-3-1) (before ultrasonic treatment) obtained in Comparative Example 2-3-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of ezetimibe, followed by stirring, and thus, a test suspension (C2-3-2) was prepared. However, measurement of the particle size of particles (before ultrasonic treatment (a) and after ultrasonic treatment (b)) was not performed (Table 23), because this test suspension (C2-3-2) had already lost its fluidity and solidified, and apparent aggregation was observed visually.

Comparative Reference Example 2-3: Production and Evaluation of Test Suspension Using Macrogol 400

[0141] A test suspension (CR2-3) was obtained in the same manner as in Comparative Example 2-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 23 shows the results. Note that the test suspension (CR2-3) lost its fluidity and was partially solidified.

TABLE-US-00023 TABLE 23 Com- Com- Com- parative parative parative Reference Example Example Example 2-3 2-3-1 2-3-2 Ingredients Ezetimibe 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 0 0 0 Agent Macrogol 400 4 4 4 Amount of Anti-Aggregation — — — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 6.54 the fluidity was lost Particle Treatment (a) Size After Ultrasonic 3.03 not to measured (μm) Treatment (b) Difference ((a) − (b)) 3.51

[0142] As is clear from Tables 15 to 23 above, it can be seen that even though the test suspensions produced in the examples above contained silicone oil, aggregation of ezetimibe was appropriately prevented by the anti-aggregation agents.

Example 3: Test Suspensions Containing Tolvaptan) (Example 3-1-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0143] A tolvaptan suspension was prepared by adding tolvaptan as a poorly water-soluble drug, carboxymethylcellulose sodium, mannitol, and sodium dihydrogen phosphate monohydrate to purified water to the following concentrations. [0144] Tolvaptan: 30% by mass [0145] Carboxymethylcellulose sodium: about 1.248% by mass [0146] Mannitol: about 6.24% by mass [0147] Sodium dihydrogen phosphate monohydrate: about 0.111% by mass

[0148] To 1 g of the tolvaptan suspension was added polyoxyethylene cetyl ether as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of tolvaptan contained in the suspension, followed by stirring. To this suspension was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 0.5 parts by mass with respect to 100 parts by mass of tolvaptan, followed by stirring, and thus, a test suspension (E3-1-1) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 24 shows the results.

Example 3-1-2: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0149] To the test suspension (E3-1-1) (before ultrasonic treatment) obtained in Example 3-1-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of tolvaptan, followed by stirring, and thus, a test suspension (E3-1-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 24 shows the results.

Reference Example 3-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0150] A test suspension (R3-1) was obtained in the same manner as in Example 3-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 24 shows the results.

TABLE-US-00024 TABLE 24 Reference Example Example Example 3-1 3-1-1 3-1-2 Ingredients Tolvaptan 100 100 100 (Parts by Silicone Oil 0 0.5 5 mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 14.80 14.38 13.17 Particle Treatment (a) Size After Ultrasonic 12.07 13.91 11.57 (μm) Treatment (b) Difference ((a) − (b)) 2.73 0.47 1.60 .sup.1)Polyoxyethylene Cetyl Ether

Example 3-2-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0151] A test suspension (E3-2-1) was obtained in the same manner as in Example 3-1-1, except that, to 1 g of the tolvaptan suspension prepared in Example 3-1-1, polyoxyethylene (160) polyoxypropylene (30) glycol (having an average molecular weight of 8905) was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of tolvaptan contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 25 shows the results.

Example 3-2-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0152] To the test suspension (E3-2-1) (before ultrasonic treatment) obtained in Example 3-2-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of tolvaptan, followed by stirring, and thus, a test suspension (E3-2-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 25 shows the results.

Reference Example 3-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0153] A test suspension (R3-2) was obtained in the same manner as in Example 3-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 25 shows the results.

TABLE-US-00025 TABLE 25 Reference Example Example Example 3-2 3-2-1 3-2-2 Ingredients Tolvaptan 100 100 100 (Parts by Silicone Oil 0 0.5 5 mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 13.20 12.55 13.29 Particle Treatment (a) Size After Ultrasonic 12.85 12.34 13.65 (μm) Treatment (b) Difference ((a) − (b)) 0.35 0.21 -0.36 .sup.1)Polyoxyethylene (160) Polyoxypropylene (30) Glycol

Example 3-3-1: Production and Evaluation of Test Suspension Using Polysorbate 20

[0154] A test suspension (E3-3-1) was obtained in the same manner as in Example 3-1-1, except that, to 1 g of the tolvaptan suspension prepared in Example 3-1-1, polysorbate 20 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of tolvaptan contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 26 shows the results.

Example 3-3-2: Production and Evaluation of Test Suspension Using Polysorbate 20

[0155] To the test suspension (E3-3-1) (before ultrasonic treatment) obtained in Example 3-3-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of tolvaptan, followed by stirring, and thus, a test suspension (E3-3-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 26 shows the results.

Reference Example 3-3: Production and Evaluation of Test Suspension Using Polysorbate 20

[0156] A test suspension (R3-3) was obtained in the same manner as in Example 3-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 26 shows the results.

TABLE-US-00026 TABLE 26 Reference Example Example Example 3-3 3-3-1 3-3-2 Ingredients Tolvaptan 100 100 100 (Parts by Silicone Oil 0 0.5 5 mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 13.29 13.13 12.46 Particle Treatment (a) Size After Ultrasonic 12.63 12.13 11.96 (μm) Treatment (b) Difference ((a) − (b)) 0.66 1.00 0.50 1.sup.)Polysorbate 20

Example 3-4-1: Production and Evaluation of Test Suspension Using Polysorbate 80

[0157] A test suspension (E3-4-1) was obtained in the same manner as in Example 3-1-1, except that, to 1 g of the tolvaptan suspension prepared in Example 3-1-1, polysorbate 80 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of tolvaptan contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 27 shows the results.

Example 3-4-2: Production and Evaluation of Test Suspension Using Polysorbate 80

[0158] To the test suspension (E3-4-1) (before ultrasonic treatment) obtained in Example 3-4-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of tolvaptan, followed by stirring, and thus, a test suspension (E3-4-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 27 shows the results.

Reference Example 3-4: Production and Evaluation of Test Suspension Using Polysorbate 80

[0159] A test suspension (R3-4) was obtained in the same manner as in Example 3-4-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 27 shows the results.

TABLE-US-00027 TABLE 27 Reference Example Example Example 3-4 3-4-1 3-4-2 Ingredients Tolvaptan 100 100 100 (Parts by Silicone Oil 0 0.5 5 mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 10.83 12.26 10.17 Particle Treatment (a) Size After Ultrasonic 9.02 11.83 8.49 (μm) Treatment (b) Difference ((a) − (b)) 1.81 0.43 1.68 .sup.1)Polysorbate 80

Comparative Example 3-1-1: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0160] A test suspension (C3-1-1) was obtained in the same manner as in Example 3-1-1, except that no anti-aggregation agent was added to 1 g of the tolvaptan suspension prepared in Example 3-1-1. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 28 shows the results.

Comparative Example 3-1-2: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0161] To the test suspension (C3-1-1) (before ultrasonic treatment) obtained in Comparative Example 3-1-1 was added the 1% silicone oil emulsion such that amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of tolvaptan, followed by stirring, and thus, a test suspension (C3-1-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 28 shows the results.

Comparative Reference Example 3-1: Production and Evaluation of Test Suspension Containing No Anti-Aggregation Agent

[0162] A test suspension (CR3-1) was obtained in the same manner as in Comparative Example 3-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 28 shows the results.

TABLE-US-00028 TABLE 28 Com- Com- Com- parative parative parative Reference Example Example Example 3-1 3-1-1 3-1-2 Ingredients Tolvaptan 100 100 100 (Parts by Silicone Oil 0 0.5 5 mass) Anti-Aggregation 0 0 0 Agent Amount of Anti-Aggregation — 0 0 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 11.35 14.80 25.66 Particle Treatment (a) Size After Ultrasonic 9.98 12.39 18.99 (μm) Treatment (b) Difference ((a) − (b)) 1.37 2.41 6.67

[0163] As is clear from Tables 24 to 28 above, it can be seen that even though the test suspensions produced in the examples above contained silicone oil, aggregation of tolvaptan was appropriately prevented by the anti-aggregation agents.

Example 4: Test Suspensions Containing Sorafenib Tosylate Example 4-1-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0164] A sorafenib tosylate suspension was prepared by adding sorafenib tosylate as a poorly water-soluble drug, carboxymethylcellulose sodium, mannitol, and sodium dihydrogen phosphate monohydrate to purified water to the following concentrations. [0165] Sorafenib tosylate: 30% by mass [0166] Carboxymethylcellulose sodium: about 1.248% by mass [0167] Mannitol: about 6.24% by mass [0168] Sodium dihydrogen phosphate monohydrate: about 0.111% by mass

[0169] To 1 g of the sorafenib tosylate suspension was added polyoxyethylene cetyl ether as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of sorafenib tosylate contained in the suspension, followed by stirring. To this suspension was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 0.5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (E4-1-1) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 29 shows the results.

Example 4-1-2: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0170] To the test suspension (E4-1-1) (before ultrasonic treatment) obtained in Example 4-1-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (E4-1-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 29 shows the results.

Reference Example 4-1: Production and Evaluation of Test Suspension Using Polyoxyethylene Cetyl Ether

[0171] A test suspension (R4-1) was obtained in the same manner as in Example 4-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 29 shows the results.

TABLE-US-00029 TABLE 29 Reference Example Example Example 4-1 4-1-1 4-1-2 Ingredients Sorafenib Tosylate 100 100 100 Mass) Silicone Oil 0 0.5 5 (Parts by Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 39.16 40.84 40.26 Particle Treatment (a) Size After Ultrasonic 30.98 31.60 26.51 (μm) Treatment (b) Difference ((a) − (b)) 8.18 9.24 13.75 .sup.1)Polyoxyethylene Cetyl Ether

Example 4-2-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0172] A test suspension (E4-2-1) was obtained in the same manner as in Example 4-1-1, except that, to 1 g of the sorafenib tosylate suspension prepared in Example 4-1-1, polyoxyethylene (160) polyoxypropylene (30) glycol (having an average molecular weight of 8905) was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of sorafenib tosylate contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 30 shows the results.

Example 4-2-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0173] To the test suspension (E4-2-1) (before ultrasonic treatment) obtained in Example 4-2-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (E4-2-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 30 shows the results.

Reference Example 4-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (160) Polyoxypropylene (30) Glycol

[0174] A test suspension (R4-2) was obtained in the same manner as in Example 4-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 30 shows the results.

TABLE-US-00030 TABLE 30 Reference Example Example Example 4-2 4-2-1 4-2-2 Ingredients Sorafenib Tosylate 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 38.03 37.68 37.83 Particle Treatment (a) Size After Ultrasonic 30.23 27.79 26.25 (μm) Treatment (b) Difference ((a) − (b)) 7.80 9.89 11.58 .sup.1)Polyoxyethylene (160) Polyoxypropylene (30) Glycol

Example 4-3-1: Production and Evaluation of Test Suspension Using Polysorbate 20

[0175] A test suspension (E4-3-1) was obtained in the same manner as in Example 4-1-1, except that, to 1 g of the sorafenib tosylate suspension prepared in Example 4-1-1, polysorbate 20 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of sorafenib tosylate contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 31 shows the results.

Example 4-3-2: Production and Evaluation of Test Suspension Using Polysorbate 20

[0176] To the test suspension (E4-3-1) (before ultrasonic treatment) obtained in Example 4-3-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (E4-3-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 31 shows the results.

Reference Example 4-3: Production and Evaluation of Test Suspension Using Polysorbate 20

[0177] A test suspension (R4-3) was obtained in the same manner as in Example 4-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 31 shows the results.

TABLE-US-00031 TABLE 31 Reference Example Example Example 4-3 4-3-1 4-3-2 Ingredients Sorafenib Tosylate 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation Ingredient — 8 0.8 per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 40.11 38.48 40.39 Particle Treatment (a) Size After Ultrasonic Treatment 26.62 27.34 26.39 (μm) (b) Difference ((a) − (b)) 13.49 11.14 14.00 .sup.1)Polysorbate 20

Example 4-4-1: Production and Evaluation of Test Suspension Using Polysorbate 80

[0178] A test suspension (E4-4-1) was obtained in the same manner as in Example 4-1-1, except that, to 1 g of the sorafenib tosylate suspension prepared in Example 4-1-1, polysorbate 80 was added as an anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of sorafenib tosylate contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 32 shows the results.

Example 4-4-2: Production and Evaluation of Test Suspension Using Polysorbate 80

[0179] To the test suspension (E4-4-1) (before ultrasonic treatment) obtained in Example 4-4-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (E4-4-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 32 shows the results.

Reference Example 4-4: Production and Evaluation of Test Suspension Using Polysorbate 80

[0180] A test suspension (R4-4) was obtained in the same manner as in Example 4-4-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 32 shows the results.

TABLE-US-00032 TABLE 32 Reference Example Example Example 4-4 4-4-1 4-4-2 Ingredients Sorafenib Tosylate 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 4 4 4 Agent.sup.1) Amount of Anti-Aggregation — 8 0.8 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 39.20 40.19 39.38 Particle Treatment (a) Size After Ultrasonic 25.13 26.87 27.06 (μm) Treatment (b) Difference ((a) − (b)) 14.07 13.32 12.32 .sup.1)Polysorbate 80

Comparative Example 4-1-1: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0181] A test suspension (C4-1-1) was obtained in the same manner as in Example 4-1-1, except that no anti-aggregation agent was added to 1 g of the sorafenib tosylate suspension prepared in Example 4-1-1. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 33 shows the results.

Comparative Example 4-1-2: Production and Evaluation of Test Suspension (Blank) Containing No Anti-Aggregation Agent

[0182] To the test suspension (C4-1-1) (before ultrasonic treatment) obtained in Comparative Example 4-1-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (C4-1-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 33 shows the results.

Comparative Reference Example 4-1: Production and Evaluation of Test Suspension Containing No Anti-Aggregation Agent

[0183] A test suspension (CR4-1) was obtained in the same manner as in Comparative Example 4-1-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 33 shows the results.

TABLE-US-00033 TABLE 33 Com- Com- Com- parative parative parative Reference Example Example Example 4-1 4-1-1 4-1-2 Ingredients Sorafenib Tosylate 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 0 0 0 Agent Amount of Anti-Aggregation — 0 0 Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 37.80 46.81 52.91 Particle Treatment (a) Size After Ultrasonic 24.22 29.68 31.58 (μm) Treatment (b) Difference ((a) − (b)) 13.58 17.13 21.33

Comparative Example 4-2-1: Production and Evaluation of Test Suspension Using Sodium Lauroylsarcosinate

[0184] A test suspension (C4-2-1) was obtained in the same manner as in Example 4-1-1, except that, to 1 g of the tolvaptan suspension prepared in Example 4-1-1, sodium lauroylsarcosinate was added instead of the anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of sorafenib tosylate contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 34 shows the results.

Comparative Example 4-2-2: Production and Evaluation of Test Suspension Using Sodium Lauroylsarcosinate

[0185] To the test suspension (C4-2-1) (before ultrasonic treatment) obtained in Comparative Example 4-2-1 was added the 1% silicone oil emulsion such that the amount of silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (C4-2-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 34 shows the results.

Comparative Reference Example 4-2: Production and Evaluation of Test Suspension Using Sodium Lauroylsarcosinate

[0186] A test suspension (CR4-2) was obtained in the same manner as in Comparative Example 4-2-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 34 shows the results. Note that the test suspension (CR4-2) lost its fluidity and was partially solidified.

TABLE-US-00034 TABLE 34 Com- Com- Com- parative parative parative Reference Example Example Example 4-2 4-2-1 4-2-2 Ingredients Sorafenib Tosylate 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 0 0 0 Agent Sodium 4 4 4 Lauroylsarcosinate Amount of Anti-Aggregation — — — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Nass) Average Before Ultrasonic 49.78 76.58 71.19 Particle Treatment (a) Size After Ultrasonic 32.49 34.71 35.00 (μm) Treatment (b) Difference ((a) − (b)) 17.29 41.87 36.19

Comparative Example 4-3-1: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0187] A test suspension (C4-3-1) was obtained in the same manner as in Example 4-1-1, except that, to 1 g of the tolvaptan suspension prepared in Example 4-1-1, polyoxyethylene (20) polyoxypropylene (20) glycol (having an average molecular weight of approximately 2000 (and less than 3000)) was added instead of the anti-aggregation agent in an amount corresponding to 4 parts by mass with respect to 100 parts by mass of sorafenib tosylate contained in the suspension. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 35 shows the results.

Comparative Example 4-3-2: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0188] To the test suspension (C4-3-1) (before ultrasonic treatment) obtained in Comparative Example 4-3-1 was added the 1% silicone oil emulsion such that amount of the silicone oil contained in the resulting suspension was 5 parts by mass with respect to 100 parts by mass of sorafenib tosylate, followed by stirring, and thus, a test suspension (C4-3-2) was obtained. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 35 shows the results.

Comparative Reference Example 4-3: Production and Evaluation of Test Suspension Using Polyoxyethylene (20) Polyoxypropylene (20) Glycol

[0189] A test suspension (CR4-3) was obtained in the same manner as in Comparative Example 4-3-1, except that the 1% silicone oil emulsion was not added. The particle size of particles contained in the obtained test suspension before ultrasonic treatment (a) and the particle size of particles contained in the test suspension after ultrasonic treatment (b) were measured. Table 35 shows the results. Note that the test suspension (CR4-3) lost its fluidity and was partially solidified.

TABLE-US-00035 TABLE 35 Com- Com- Com- parative parative parative Reference Example Example Example 4-3 4-3-1 4-3-2 Ingredients Sorafenib Tosylate 100 100 100 (Parts by Silicone Oil 0 0.5 5 Mass) Anti-Aggregation 0 0 0 Agent Polyoxyethylene (20) 4 4 4 Polyoxypropylene (20) Glycol Amount of Anti-Aggregation — — — Ingredient per 1 Part by Mass of Silicone Oil (Parts by Mass) Average Before Ultrasonic 49.47 53.99 58.12 Particle Treatment (a) Size After Ultrasonic 32.61 35.24 30.39 (μm) Treatment (b) Difference ((a) − (b)) 16.86 18.75 27.73

[0190] As is clear from Tables 29 to 35 above, it can be seen that even though the test suspensions produced in the examples above contained silicone oil, aggregation of sorafenib tosylate was appropriately prevented by the anti-aggregation agents.

[0191] Thus, it can be seen that the anti-aggregation agents used in the examples above are useful for preventing poorly water-soluble drugs, such as aripiprazole, ezetimibe, tolvaptan, and sorafenib tosylate, from aggregating when suspended in an aqueous dispersion medium in the presence of silicone oil. Furthermore, it can also be seen that the coexistence of such an anti-aggregation agent with a poorly water-soluble drug in a medical device including a container whose inner wall is treated with silicone oil is useful.

INDUSTRIAL APPLICABILITY

[0192] The present invention is useful in the fields of manufacturing pharmaceuticals and medical devices, for example.